Mucoangin®

Notice of AGM 2020

View PDFof Notice of AGM 2020

Signed Financials FY 2019-20

View PDFof Signed Financials FY 2019-20

PRESS RELEASE 31 Aug 2020 at 08:00

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 percent in adults

Read more on Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 percent in adults

PRESS RELEASE 18 Aug 2020 at 10:00

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

Read more on Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

NEWS

Emotional Bonds—Protected with Complete Care!

Read more on Emotional Bonds—Protected with Complete Care!

PRESS RELEASE 31 Jul 2020 at 08:25

Boehringer Ingelheim launches NexGard® and Broadline® in India for comprehensive parasite control in companion animals

Read more on Boehringer Ingelheim launches NexGard® and Broadline® in India for comprehensive parasite control in companion animals

PRESS RELEASE 31 Jul 2020 at 08:00

Empagliflozin meets primary endpoint in Phase III heart failure trial

Read more on Empagliflozin meets primary endpoint in Phase III heart failure trial

NEWS

India should focus on healthcare innovation and access post-COVID-19

Read more on India should focus on healthcare innovation and access post-COVID-19

PRESS RELEASE 30 Jun 2020 at 10:00

Boehringer Ingelheim and Cipla forge partnership to co-market three oral anti-diabetic drugs

Read more on Boehringer Ingelheim and Cipla forge partnership to co-market three oral anti-diabetic drugs

PRESS RELEASE 22 May 2020 at 18:44

Drugs Controller General (India) approves Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)

Read more on Drugs Controller General (India) approves Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)

NEWS

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

Read more on Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

NEWS

Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio

Read more on Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio

NEWS

Boehringer Ingelheim expands immuno-oncology portfolio by acquiring Northern Biologics’ preclinical cancer antibody pipeline

Read more on Boehringer Ingelheim expands immuno-oncology portfolio by acquiring Northern Biologics’ preclinical cancer antibody pipeline

NEWS

BoehringerIngelheim, CDR-Life collaborate to develop antibody fragment-based therapeutics for geographic atrophy

Read more on BoehringerIngelheim, CDR-Life collaborate to develop antibody fragment-based therapeutics for geographic atrophy

NEWS

Boehringer Ingelheim and CDR-Life to develop Antibody Fragment-based Therapeutics for Geographic Atrophy

Read more on Boehringer Ingelheim and CDR-Life to develop Antibody Fragment-based Therapeutics for Geographic Atrophy

NEWS

Boehringer Ingelheim expanding immuno-oncology portfolio

Read more on Boehringer Ingelheim expanding immuno-oncology portfolio

PRESS RELEASE 15 May 2020 at 17:09

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline

Read more on Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline

PRESS RELEASE 15 May 2020 at 16:06

Boehringer Ingelheim Collaborates with CDR-Life

Read more on Boehringer Ingelheim Collaborates with CDR-Life

NEWS

BI India in News

Giving highest priority to ensure uninterrupted supply of medicines: Sharad Tyagi, Boehringer Ingelheim, India

Search form

Mucoangin^®